Abstracts Vol. 1 [International Conference on AIDS (11th: 1996: Vancouver, Canada)]

3TC, SEE Lamivudine
No.A.38 I Mo.B. 1306, Mo.B. 1328,
MNo. D.49 2, Tu. B.2 I1I5,Tu. B. 2 I31,Tu. C.445,
We.B.3 I119, We.B.3 121
aboriginal people
Mo.C. 1420, No.C. 1673, Mo.D. 1895,
Mo.D.1898, Mo.D. 1906, No.D.48 1,
Mo.D.482 Mo.D.483, Mo.D484,
Pub.D. I1362, Th.C.4470, Th.C.45 12,
Th. D.4906, Th. D.5029, Th. D.5 127,
Tu.A. I163, Tu.C.2627, Tu.C.2630,
Tu.D.2833, We.C.3494. We.D.484
abortion
Pub.D. 131I5, Th.C. I122, Th.C.4594,
Tu.C.2456
abstinence, sexual
MoC. 1629, Mo.D. 1735, Mo.D. 175 1,
Mo.D. I1874, Pub.C. 11I95, Th.C.4429,
Tu.C.330,Tu.D.2709
ABT-538
Mo.B. 137, No.B. 1197, Mo.B. I1198,
Mo.B. I1199, No.8. 1200, No.8.1201,
No.8.171, No.B.175, Mo.B.4 I 1,
Th.B.4348,Tu.B.2 124, We.B.3 127,
We.B.551
acemannan
Th.C.4614
activation markers
Pub.A. I1008, Th.A. I161,Th.A. I165,
Th.A.403 I, Th. B. I 76, Th.B8.4285,
Th. B.42 93, Th. B.4297, Tu.A.2006,
Tu.A.2008, Tu.A.2026, Tu.A.2042,
Tu.A.2046, Tu.B.23 I14, We.A.3050,
We.A.3066, We.A.3070, We.A.3087,
We.A.309 I, We.A.503
activism
No.B. 1159, No.B.1206, No.D. 1742,
Pub.D. I1307, Pub.D. 1457, Pub.D. 149 1,
Pub.D. I 494, Th.C.4409, Th.C.4545,
Th.C.4685, Th.C.4840. Th.D.232,
Th.D.233,Th.D.25 I,Th.D.494 1,
Th.D.5000,Th.D.5 I13 I,Th.D.5 1 32,
Th.D.5 I 48,Th.D.5 I 99,Tu.B.52 I,
Tu.C.2663,Tu.D.234,Tu.D.27 19,
Tu. D.272 9, Tu. D.27 38, Tu. D.2775,
lTu. D.2807, Tu. D.2808, Tu. D.2849,
Tu.D.2922, Tu.D.2939, Tu.D.2944,
Tu. D.2946, Tu. D.2947, Tu. D.2949,
Tu.D.295 I, Tu.D.350,Tu.D.480, Tu.D.482,
Tu.D.484,Tu.D.4, We.C.444, We.D.3609,
We.D.366 I, We.D.3849, We.D.3903
activities of daily living
No.8.551, No.D.1881, Pub.D.1413,
Pub.D. I 484,Th.D.5094,Th.D.5095,
Th.D.5 I 08, Tu. B. I 74, Tu. B.2 I147, Tu.8B.2 34,
Tu.D.2858,Tu.D.2867, We.D.3690,
We.D.369 I, We.D.3796
acute infection
No.A. 1071, No.A.282, No.8.1330,
L No.C.324, Pub.A.1004, Pub.A.1009,
> Pub.8. I1054, Th.B.4350, Tu.A.2048,
Tu.8B.2 12 2, Tu.B.2 I167, Tu.C.2694,
C We.A.3008, We.A.380, We.A.383,
c~We.A.384, We.B.3 I128, We.B.533
acyclovir
cn No.8. 1141, No.B.430,Th.B.300,
0~ Th.B.4200,Th.8.4202,Th.8.4223,

Th.C.4395, Th.C.4396, Th.C.4397,
476 Th.C.4399,-Th.C.44 13, Fh.C.44 I18.

Th.C.443 I,Th.C.4433,Th.C.4434,
Th.C.4435, Th.C.4436, Th.C.4437,
Th.C.4444,Th.C.4837, Th.C.4842,
Th. D.440, Th. D.44 2, Th. D.44 3, Th. D.444,
Th.D.446,Th.D.4879, Th.D.4903,
Th.D.4905,Th.D.49 I5,Th.D.49 I6,
Th. D.491I7, Th. D.491 8, Th. D.4920,
Th.D.4924, Th.D.4925, Th.D.4928,
Th.D.4929,Th.D.49 3 I,Thi.D.5 105,
Tu.B.2207, Tu.C.239 5, Tu.C.2405,
Tu.C.2422, Tu.C.2432, Tu.C.2482,
Tu.C.262 I,Tu.C.2662, Tu.C.3 30, Tu.C.33 1,
Tu.C.332,Tu.D.270 I,Tu.D.2703,
Tu.D.2723, Tu.D.2792, Tu.D.2799,
Tu.D.2805, Tu.D.28 I5, Tu.D.28 I18,
Tu.D.28 I 9,Tu.D.2867, Ju.D.2873,
Tu.D.2947,Tu.D.47 I.We.C.205,
We.C.3443, We.C 3508, We.D. 135,
We.D.35 1, We.D.3663, We.I3.3 75 1,
We.D.3780, We.D.378 I, We.D.3797,
We.D.38 I13
adoption
Pub.D. I1298, We.D.3908
adrenal gland
Tu.B.2270,Tu.B.2378, No.8. 1202,
No.8.1204, No.B.173, Tub.8. 1045,
Th.A.4077, Th.B.41 75, Tu. B.21I 17,
Tu.8.2 I I9,Tu.8.2263,Tu.8.229 I,
Tu.8.230 I,Tu.8.2304, We.A.3 101,
We.8.3 I120, We.8.3 I122, We.8.3296,
We.8.3336, We.C.2 13
advocacy
No.C,1610, No.C. 1630, No.D. 1697,
No.D. 1833, No.D. 1895, No.D. 1904,
No.D,1931, No.D. 1950, No.D.243,
No.D.480, Pub.C. 1 190, Pub.C. 1228,
Pub.C. I1258, Pub.D. 1342, Pub.D. I1376,
Pub.D. I 436,Th.C.4535, Th.C.4559,
Th.C.4584, Th.C.4677, Th.C.4736,
Th.C.4797, Th.C.4823, Th.D. 135,
Th.D.232, Th.D.4864, Th.D.4943,
Th. D.4945,,Th. D.4997, Th. D.5000,
Th.D.500 I, Th.D.5006, Th.D.5007,
Th. D.5009, Th. D.501I5, Th. D.5 I131,
Th.D.5 I 33,Th.D.5 14 I,Th.D.5 144,
Th.D.5 I 47,Th.D.5 I190, Tu.C.2638,
Tu.C.2663,Tu.D. I 30,Tu.D.233,Tu.D.234,
Tu.D.2947,Tu.D.2919, uD.350, Iu.D.48 1,
Tu.D.483,Tu.D.485, We.B.3 166,
We.C.3494, We.D,2 32, We.D 3644,
We.D.3648, We.D.3696, Wc.D.3784,
We.D.3849, We.D.3864, We.D.3893
affected communities
No.8. 1136, No.B 1296, Mu..420,
No.C,1484, Mo.. 1899, No. 1.901,
No.D. 1905, No.D.233, No.D.48 I,
Pub.D. I303, Pub.D.1307, Pub.D. 1334,
Pub.D. I1349, Pub.D, I1382, Puhb.L). I422,
Pub.D. 1491,Th.C.4523. Th.C.4642,
Th.C.4668, Th.C.46/9.ThC.4 X63,
Th.D. I 30,Th.D.23 I,Th.D.36 I,Th.D.4882,
Th.D.5 1 4 I, Th.D.5 I169, TIvD.5 172,
Tu.B.220 I,Tu.D, I132, Eu.D.243, Tu.D.2867,
Tu. D.2924, Tu. D.29 3 3, Tu. D.29 37,
Tu. D.2939,Tu.D.2956, We.D. 3709,
We.D.3720, We.D.3844
affected individuals

AIDS dementia complex (ADC)
No.8.314, No.D. 1893, No.D. 1894,
Pu b. B.I1066, Th. B. I185, Th. B.425 5,
Th.B.4259,Th.B.426 I,Tu.A, 143,
Tu.A.20 I13, Tu.A.20 I18, Tu.A.2055,
Tu.8.2278, We.B.3283, We.8.3284,
We.B.3288, No.C, 1497, No.C. 1650,
No.D.374
AIDS policy, SEE public policy
Pub.C.l I114, Pub.C.l1190, Pub.C.l1195,
Pub.C. 1209, Pub.C, 1275, Pub.D. I1324,
Pub.D. I 399,Th.C.4525,Th.C.453 1,
Th.C.4760, Th.C.48 I15, Th.C.4836,
Th. D.4944, Th. D.4994, Th. D.4997,
Th.D.5005, Th.D.5007, Th.D.5009,
Th.D.50 I 4,Th.D.50 I 5,Th.D.5 147,
Tu.A.2020, Tu. B.2203, Tu.C.2622,
We.D.232We.D.234, We.D.367 1,
We.D.493
AIDS resources
No.8.195, No.D. 1905, No.D.235,
Pub.D. I1430, Th.C.20 I, Th.C.45 I16,
Th.C.4545.Th.C.4775,Th.C.482 1,
Th.C.4828, Th.C.4840, Th.D.5 144,
Tu. B.2 13 8, Tu. B.2 I139, Tu. B.2 369,
We.D.3694, We.D.3720, We.D.3779,
We.D.3884, We.D.3890, We.D.389 1,
We.D.484
AIDS service organisations (ASO)
No.D. 1762, No.D,1794, No.D. 1904,
No.D,1933, No.D.233, No.D.374,
Mo.D.492, Pub.C. 1202, Pub.C, 125 1,
Pub.D. 1298, Pub.D. I1387, Pub.D. 1408,
Pub.D. 1417, Pub.D. 1439, Pub.D. 1490,
Pub.D. 1492, Pub.D. 150 1,Th.C.4462,
Th.C.4550,Th.C.4582,,Th.C.4762,
Th.C.4773,Th.C.4779,Th.C.4785,
Th.C.4823, Th.D.235, Th.D.4942,
Th.D.506 I,Th.D.5067,Th.D.520 1,
Th.D.5204,Tu.C.2448,Tu.C.2668,
Tu.D.232,Tu.D.2732,Tu.D.2757,
Il. D.2 785, fu.D.2839, Tu.D.2876,
Tu.D.2879.Tu.D.2926,Tu.D.350, Tu.D.356,
Tu.D.36 I,Tu.D.480,Tu.D.603, We.B,172,
We.C.3484, WeD1.25 I, We.D.3668,
We.D.3687, We.D.3708, We.D.376 1,
We.D.3762, We.D.3777, We.D.3779,
We.D.3795, We.D.3843, We.D.3844,
We.D.3848, We.D.3854, We.D.3874,
We.D.3897, We.D.3903, We.D.39 12,
We.D.493, We.D.6 10
AIDS-related complex (ARC)
No.8. I1126, Pub.C. 1 107, Pub.C. I1192,
Pub.D. I 458, Th.B.4 I107, Tu.C.432,
We.B.3 195, We.C 341 3, We.D.3894
alcohol
No.C. 1649, No.D. 1719, No.D. 1724,
No.D,1734. No.D,1735, No.D. 1906,
Pub.C. I I25, Pub.D. I135 I,Th.B.4269,
Th.B.42801,Th.C.4526,Th.D.4923,
Tu.C.24 I 4,Tu.C.2555, We.C.560
alpha-APA, SEE loviride
Pub.D. 1453
alternative therapies
No.A. 1054, No.A. 1062, No.A. 1096,
No.8. 1172, No.8.1315, No.8.180,
No.8.181, No.8.182, No.8. 183,

Tu.B.2 I160, Tu.B.2 303, Tu.D.28 14,
We.B.175

amoxicillin
No.8. 121 7,Tu.D.2887
amphotericin B
N o.B.1 2 32, Th.A.4062, Th. B.4208,
Th.B.4220,Th.D.498 I,Tu.B.2 196,
Tu.B.2199, We.B.33 16
amylase
Th.8.4269
anal cancer
No.D.492, Pub.8, 1060, Pub.D. I1333,
Th.B.4 I 36,Tu.C.433, We.B.540, We.B.54 I
anal sex
No.D. 1725, Mo.D. 1852, No.D.49 1,
Pub.C.l112 1,Pub.C.l1162, Pub.C.I1173,
Pub.D. I1304, Pub.D. 1305, Pub.D. 131 7,
Th.D.46 I,Th.D.5 I 94,Tu.C.2395,
Tu.C.2400,Tu.C.2404,Tu.C.245 1,
Tu. C.2626, Tu. D.2700, Tu. D.2708,
Tu.D.27 I 3,Tu.D.2967,Tu.D.365,
We.C.348 I, We.C.440, We.D.48 I
anemia
No.8. I119 I,Th.B.4285
angioimmunoblastic lymphadenopathy
Pub.B. 1060
angular stomatitis
No.8.1233
animal models, baboon
Tu.B.40 I,Tu.B.52 I
animal models, cat
No.A. 101,Th.C.32 I,Tu.A.264
animal models, chimpanzee
No.A.404, No.A.406,Tu.A.20 I 1,
Tu.A.2 I108, Tu.A.5 I10, Tu. D.603,
We.A.3078, We.A.383
animal models, macaque
No.A. 102, Mo.A. 104, Mo.A. 1041,
No.A.400, No.A.403, No.A.404,
Pub.A. I1009, Th.A. I142, Th.A.275,
Tu.A.2083,Tu.C.2695, We.A. 140,
We.A. 142, We.A. 143, We.A. I144,
We.A. I161, We.A.272, We.A.28 1,
We.A.282, We.A.283, We.A.285,
We.A.3002, We.A.3008, We.A.3009,
We.A.384, We.A.385, We.A.392,
We.A.395, We.A.400, We.A.40 I
animal models, mouse
No.A. 1069, No.A.274,Th.8.4 191,
Tu.A.262,Tu.A.263, We.A.265,
We.A.300 I, We.A.3003, We.A.3004,
We.A.3005, We.A.3006, We.A.30 10
animal models, other
No.8. I139 I,Tu.A.2059
anonymity
No.8. I 180, Pub.C. I247, Th.C.4596,
Th.C.4599, Th.C.46 I16, Th.C.4756,
Th.D.360, Yh.D.4954, We.C.350 1,
We.D.3729
anti-CD3 antibody
Th.B.433 I,Tu.A.380 We.A.307 I
anti-HIV serum
No.A.273, No.8. 1147, No.B. 1177,
Th.A.4005, We.A.30 16, We.A.304 I
anti-interferon immunoglobulin
Th.B. 174, Pub.8. I1OS I,Th.A. 163
anti-tat therapy
No.A. 1046, No.A. 1094
anti-V3 loop antibody

Th.C.46 I 4,Tu.B.2369, We.A.3040,
We.A.3045, We.B.3207, We.D.3678